Bone Marrow News and Research

RSS

Bone Marrow is the soft, sponge-like tissue in the center of most bones. It produces white blood cells, red blood cells, and platelets.

Research presented at AIDS 2012 conference renews hope of cure for AIDS

Two studies presented at the XIX International AIDS Conference (AIDS 2012) and one published Wednesday in the British journal Nature "have given researchers renewed hope that a cure for AIDS may be possible," the Washington Post reports.

28 Jul 2012

ARIAD Pharmaceuticals commences ponatinib Phase 3 trial in newly diagnosed CML

ARIAD Pharmaceuticals, Inc. today announced the initiation of the randomized Phase 3 trial of ponatinib, its investigational pan-BCR-ABL inhibitor, in adult patients with newly diagnosed chronic myeloid leukemia (CML).

28 Jul 2012

AIDS roundup: Researchers examine whether the disease causes premature aging; Funding and treatment gaps; Bone marrow transplant treatments

News outlets report on scientific and political issues coming up at the International AIDS Conference being held in Washington.

27 Jul 2012

First Edition: July 27, 2012

Today's headlines include reports about a new effort launched by the Obama administration and insurers to fight health care fraud.

27 Jul 2012

Bone marrow transplant eradicates traces of HIV in men

Two men with longstanding HIV infections no longer have detectable HIV in their blood cells following bone marrow transplants. The virus was easily detected in blood lymphocytes of both men prior to their transplants but became undetectable by eight months post-transplant. The men, who were treated at Brigham and Women's Hospital (BWH), have remained on anti-retroviral therapy.

27 Jul 2012

American Society of Hematology announces new grant program for biomedical research

The American Society of Hematology (ASH), the world's largest professional organization dedicated to the causes and treatment of blood disorders, today announced its commitment of $9 million over a three-year period to provide funding, in the form of bridge grants, for its hematologists whose vital research will not be accomplished due to the severe funding reductions for biomedical research.

26 Jul 2012

Child who received first stem cell trachea transplant functioning well two years on

The first child stem cell-supported trachea transplant is functioning well two years on, according to an Article published Online First in The Lancet today. The follow-up of the procedure, carried out in 2010 at Great Ormond Street Hospital (GOSH), shows that the new organ has strengthened and does not appear to have induced any signs of rejection. The 13-year-old boy who received the transplant continues to breathe normally, has grown 11 cm in height and has returned to school. He does not require any anti-rejection therapy.

26 Jul 2012

Multi-center clinical trial results demonstrate safety and efficacy of carfilzomib for multiple myeloma

Researchers from John Theurer Cancer Center at HackensackUMC, one of the nation's 50 best hospitals for cancer, played leading roles in three separate multi-center studies with the new proteasome inhibitor carfilzomib published in Blood, a major peer-reviewed scientific journal.

26 Jul 2012

FDA grants priority review to GSK’s Promacta sNDA for treatment of thrombocytopenia

Ligand Pharmaceuticals Incorporated today announced that its partner GlaxoSmithKline has been granted priority review from the US Food and Drug Administration for the supplemental new drug application for Promacta to treat thrombocytopenia in adult patients with chronic hepatitis C virus (HCV) infection.

26 Jul 2012

MRI useful for identifying bone lesions in diabetic feet

Identification of specific bone lesions in the feet of patients with diabetes can be achieved with magnetic resonance imaging, show study findings.

25 Jul 2012

bluebird bio completes $60 million Series D financing

bluebird bio, a leader in the development of innovative gene therapies for severe genetic disorders, today announced the successful completion of a $60 million Series D financing. In this round, new investors Deerfield Partners, RA Capital, Ramius Capital Group, and two undisclosed blue chip public investment funds joined existing investors ARCH Venture Partners, Third Rock Ventures, TVM Capital, and Forbion Capital Partners. In addition, Shire plc joined the round as a strategic investor.

25 Jul 2012

Giving patients a new immune system can cure Crohn's disease

Researchers at Fred Hutchinson Cancer Research Center have opened a clinical trial to test the theory that giving a patient a new immune system can cure severe cases of Crohn's disease, a chronic inflammatory condition of the gastrointestinal tract.

25 Jul 2012

Biokine receives FDA Orphan Drug designation for BKT140 to treat hematological cancers

Biokine Therapeutics Ltd. announced today that it has received Orphan Drug designation from the US Food and Drug Administration (FDA) for the mobilization of hematopoietic stem cells from bone marrow into peripheral blood for collection and subsequent transplantation in patients with hematological cancers.

24 Jul 2012

Study represents new use of bone marrow transplantation

24 Jul 2012

Positive results from BrainStorm's interim NurOwn stem cell therapy clinical trial for ALS

BrainStorm Cell Therapeutics announced today that it has completed the planned interim safety review of its Phase I/II ALS (Amyotrophic Lateral Sclerosis) clinical trial, indicating that autologous transplantation of the Company's cell therapy was well-tolerated, appears to be safe for use, and did not present any undue risks to the study participants.

23 Jul 2012

Researchers uncover protein structure that regulates blood cell formation and activity

A Finnish research team together with researchers from New York, USA, has uncovered a protein structure that regulates cell signalling and the formation of blood cells. The team's results, published in Nature Structural & Molecular Biology, the most prestigious journal in the field, shed light on the mechanisms at play in haematological disorders and provide new opportunities for the design of disease-specific treatment.

23 Jul 2012

Kyprolis for multiple myeloma receives FDA approval under accelerated approval program

The U.S. Food and Drug Administration today approved Kyprolis (carfilzomib) to treat patients with multiple myeloma who have received at least two prior therapies, including treatment with Velcade (bortezomib) and an immunomodulatory therapy. A form of blood cancer that arises from plasma cells, multiple myeloma usually grows in bone marrow, the soft, spongy tissue found inside most bones.

21 Jul 2012

FDA's approval of Kyprolis offers hope to myeloma patients, says IMF

The International Myeloma Foundation (IMF) - the oldest and largest foundation dedicated to improving the life and care of myeloma patients - says today's Food and Drug Administration approval of Onyx's Kyprolis (carfilzomib) offers hope to myeloma patients who have run out of options when available therapies have stopped working.

21 Jul 2012

Janssen-Cilag receives positive opinion from EMA CHMP for DACOGEN

Janssen-Cilag International NV announced today that the Committee for Medical Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted a positive opinion recommending approval of DACOGEN (decitabine) for Injection.

21 Jul 2012

FDA grants accelerated approval to Onyx's Kyprolis for treatment of multiple myeloma

Onyx Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval of Kyprolis (carfilzomib) for Injection, a proteasome inhibitor, indicated for the treatment of patients with multiple myeloma who have received at least two prior therapies, including bortezomib and an immunomodulatory agent, and have demonstrated disease progression on or within 60 days of completion of the last therapy.

21 Jul 2012

Bone Marrow News and Research

Further Reading

Research presented at AIDS 2012 conference renews hope of cure for AIDS

ARIAD Pharmaceuticals commences ponatinib Phase 3 trial in newly diagnosed CML

AIDS roundup: Researchers examine whether the disease causes premature aging; Funding and treatment gaps; Bone marrow transplant treatments

First Edition: July 27, 2012

Bone marrow transplant eradicates traces of HIV in men

American Society of Hematology announces new grant program for biomedical research

Child who received first stem cell trachea transplant functioning well two years on

Multi-center clinical trial results demonstrate safety and efficacy of carfilzomib for multiple myeloma

FDA grants priority review to GSK’s Promacta sNDA for treatment of thrombocytopenia

MRI useful for identifying bone lesions in diabetic feet

bluebird bio completes $60 million Series D financing

Giving patients a new immune system can cure Crohn's disease

Biokine receives FDA Orphan Drug designation for BKT140 to treat hematological cancers

Study represents new use of bone marrow transplantation

Positive results from BrainStorm's interim NurOwn stem cell therapy clinical trial for ALS

Researchers uncover protein structure that regulates blood cell formation and activity

Kyprolis for multiple myeloma receives FDA approval under accelerated approval program

FDA's approval of Kyprolis offers hope to myeloma patients, says IMF

Janssen-Cilag receives positive opinion from EMA CHMP for DACOGEN

FDA grants accelerated approval to Onyx's Kyprolis for treatment of multiple myeloma

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News